(NASDAQ: STOK) Stoke Therapeutics's forecast annual revenue growth rate of -13.3% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.33%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.05%.
Stoke Therapeutics's revenue in 2026 is $184,420,000.On average, 15 Wall Street analysts forecast STOK's revenue for 2026 to be $1,946,593,348, with the lowest STOK revenue forecast at $689,816,513, and the highest STOK revenue forecast at $4,347,583,065. On average, 13 Wall Street analysts forecast STOK's revenue for 2027 to be $3,442,043,621, with the lowest STOK revenue forecast at $1,159,355,484, and the highest STOK revenue forecast at $6,521,374,598.
In 2028, STOK is forecast to generate $7,636,366,989 in revenue, with the lowest revenue forecast at $4,741,763,930 and the highest revenue forecast at $13,359,205,922.